Background: Respiratory syncytial virus (RSV) vaccine was recommended for use during pregnancy in September 2023.
Objective: To assess pregnant persons' intentions to receive and evaluate factors associated with RSV vaccine intentions and uptake.
Study Design: We invited 1999 pregnant persons ≥18 years, between 12 and 30 weeks gestation who had received prenatal care at HealthPartners to complete an online survey during September-November 2023. Our primary outcome was intention to receive RSV vaccine. We also asked respondents about reasons to or not to receive RSV vaccine and intentions to receive other vaccines during pregnancy. We assessed RSV vaccine uptake for patients 32-36 weeks gestation between 10/12/23 (first RSV vaccine in study population) and 2/1/24. We estimated adjusted prevalence ratios (aPR) and 95 % confidence intervals (CI) between responses and intention to receive RSV vaccination and, for those eligible to receive RSV vaccine, adjusted rate ratios (aRR) and 95 % CIs for RSV vaccine uptake. We adjusted aPRs and aRRs for age, race, ethnicity, Medicaid, living with children ≤5 years, and work in healthcare and weighted by inverse probability of survey participation using Poisson regression with robust variance.
Results: 455 patients participated (23 % response), 26 % were non-white and/or Hispanic, 46 % lived with children ≤5 years, and 30 % work in healthcare; 65 % intended to receive RSV vaccine during pregnancy. Among 427 eligible respondents, 51 % received RSV vaccine. Factors associated with RSV vaccination intention and uptake included perceived vaccine effectiveness (aPR: 19.47, 95 % CI: 5.82, 65.12; aRR 3.06, 95 % CI: 1.70, 5.51) and a provider recommendation (aPR: 8.04, 95 % CI: 4.23, 15.29; aRR 3.30, 95 % CI: 1.99, 5.48). Among those not planning to receive RSV vaccine, responses suggested safety concerns.
Conclusion: Strong recommendations for receiving RSV vaccine during pregnancy from a healthcare provider incorporating information about RSV vaccine safety and effectiveness may increase vaccine uptake.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2025.126958 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequential Respiratory Syncytial Virus and Bacterial Infections in the Nasopharynx of Zambian Infants and Mothers.
Pediatr Infect Dis J
March 2025
Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee.
Background: Respiratory syncytial virus (RSV) is a major cause of severe respiratory infections in infants, especially under 5 years of age. Several studies have reported that interactions between RSV and bacteria like Streptococcus pneumoniae (SP), Moraxella catarrhalis (MC), Haemophilus influenzae (HI) and Staphylococcus aureus (SA) may influence their pathogenicity and the clinical outcome of infection. However, existing knowledge about RSV-bacterial interactions in infants comes primarily from cross-sectional studies, which cannot evaluate the influence of infection sequence on these interactions.
View Article and Find Full Text PDFGenomic Characterization of RSV in the US by Vaccination Status.
JAMA
March 2025
Department of Veterans Affairs Public Health Reference Laboratory, Palo Alto, California.
Harnessing Computational Strategies to Overcome Challenges in mRNA Vaccines.
Physiology (Bethesda)
March 2025
Department of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
In recent years, the introduction of mRNA vaccines for SARS-CoV2 and RSV has highlighted the success of the mRNA technology platform. Designing mRNA sequences involves multiple components and requires balancing several parameters, including enhancing transcriptional efficiency, boosting antigenicity, and minimizing immunogenicity. Moreover, changes in the composition and properties of delivery vehicles can also affect vaccine performance.
View Article and Find Full Text PDFSeverity of respiratory syncytial virus versus SARS-CoV-2 Omicron and influenza infection amongst hospitalized Singaporean adults: a national cohort study.
Lancet Reg Health West Pac
February 2025
National Centre for Infectious Diseases, Singapore.
Background: More data is required to contextualise respiratory-syncytial-virus (RSV) disease burden, versus other vaccine-preventable respiratory-viral-infections (RVIs) in older adults. We aimed to compare severity of RSV in hospitalized adults versus influenza/boosted COVID-19.
Methods: Retrospective population-based cohort study, including all adult RSV hospitalizations (2021-2023) in Singapore.
Chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease, and bronchiectasis, are significant global health concerns associated with recurrent exacerbations, hospitalization, and increased mortality. Preventive strategies, particularly vaccination, play a crucial role in managing these diseases by reducing infection-related exacerbations and stabilizing lung function. This review summarizes the recommendations provided by four major Italian scientific societies on vaccination against key respiratory pathogens, including respiratory syncytial virus, influenza, SARS-CoV-2, Streptococcus pneumoniae, and varicella-zoster virus (VZR), which pose serious risks to individuals with chronic respiratory conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!